Materialise reports Q2 EPS EUR0.0 vs. EUR0.07 last year

Reports Q2 revenue EUR64.83M vs. EUR68.8M last year. CEO Brigitte de Vet-Veithen commented, “Our Materialise (MTLS) Medical segment once again demonstrated its resilience, growing by almost 17% compared to the same period of 2024. At the same time increasing geo-political uncertainty and sustained macro-economic headwinds negatively impacted revenues in our Materialise Manufacturing and Materialise Software segments, and therefore also our consolidated revenue in Q2 2025. Despite revenue pressure we were able to materially improve our operational profitability in Q2 2025 compared to prior periods through structural and targeted cost control. Unfavorable effects from exchange rate fluctuations significantly impacted our quarterly financials, but we nevertheless again reported a positive net result.”